Ovarian Cancer

Data from RAINFOL-01 showed rinatabart sesutecan achieved responses in heavily pretreated platinum-resistant ovarian cancer with low or no FRα expression.

Initial phase 1/2 data showed a 73% objective response rate with ubamatamab in 11 patients with heavily pretreated low-grade serous ovarian cancer.

The European Medicines Agency’s CHMP recommended approval of relacorilant plus nab-paclitaxel for platinum-resistant ovarian cancer based on the ROSELLA trial.

Updated interim PYNNACLE trial data showed a 46% response rate with rezatapopt monotherapy in platinum-resistant/refractory ovarian cancer.

ASCO’s first living guideline for recurrent ovarian cancer recommends platinum-based doublets, selective bevacizumab, and mirvetuximab soravtansine for FRα-positive platinum-resistant disease.

Black women with epithelial ovarian cancer who lived in socially vulnerable neighborhoods had significantly worse survival than White women in similar areas.

Age of 35 years or older, stage III/IV disease, and nondysgerminoma histology were linked with worse cancer-specific survival in malignant ovarian germ cell tumors.

The FDA granted fast track designation to BI-1808 plus pembrolizumab, which produced a 24% confirmed ORR in pretreated platinum-resistant ovarian cancer.

A statistically significant OS benefit was observed with relacorilant plus nab-paclitaxel for patients with platinum-resistant ovarian cancer.

Delaying cytoreductive surgery until after 6 cycles of neoadjuvant chemotherapy did not improve DFS vs interval surgery after 3 cycles in patients with advanced high-grade epithelial ovarian cancer.

Across both pretreated cervical cancer and PROC populations, no new safety signals and low rates of treatment discontinuation were observed with DB-1311/BNT324.

In the phase 3 NRG-GY019 trial, while letrozole monotherapy was more tolerable, it did not achieve noninferiority compared with chemotherapy and letrozole.

Updated results from the phase 2 RAMP 201 trial show that avutometinib plus defactinib provides durable efficacy and a manageable safety profile in patients with LGSOC.

Final overall survival data from the phase 3 ROSELLA trial showed that the addition of relacorilant to nab-paclitaxel extended median survival to 16.0 months in patients with platinum-resistant ovarian cancer.

The FDA has removed the partial clinical hold on the phase 2 LINNET study of lorigerlimab for patients with platinum-resistant ovarian cancer and clear cell gynecologic cancer.

The FDA granted fast track designation to SIM0505, a CDH6-directed antibody-drug conjugate, for the management of platinum-resistant ovarian cancer.

Robert Coleman, MD, FACOG, FACS, discusses the significance of the relacorilant and nab-paclitaxel approval in PROC supported by phase 3 ROSELLA trial data.

The FDA granted FTD to CTIM-76, a CLDN6/CD3 bispecific antibody, for the treatment of patients with CLDN6-positive platinum-resistant ovarian cancer.

ZW191 is currently under evaluation in a phase 1 trial that has already demonstrated activity among patients with platinum-resistant ovarian cancer.

Updated data demonstrated a 14.7-month OS benefit when adding IMNN-001 to neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer.

Data from the ROSELLA trial support the approval of relacorilant plus nab-paclitaxel in this ovarian cancer population.

The MyChoice CDx was approved based on its performance determining HRD status and stratifying patients in the phase 3 PRIMA trial.

Updated results from the phase 3 KEYNOTE-B96 trial revealed that pembrolizumab plus paclitaxel with or without bevacizumab improved OS in all comers.

Relacorilant plus nab-paclitaxel improved PFS among patients with PROC who had progression after a PARP inhibitor or who were 65 years or older.